INDIA – HempStreet, India’s first and largest research to retail player in the medicinal cannabis space, has worked with MGC Pharmaceuticals Limited (MGC Pharma) to release a novel nutraceutical mouth spray for COVID-19 dubbed ArtemiC.
HempStreet and Australia-based biopharma company MGC Pharma have partnered to produce the nutraceutical mouth spray that reportedly speeds up recovery for patients with severe COVID-19 symptoms.
An observational open-label controlled clinical trial of ArtemiC showed a significant reduction in one of the primary inflammatory markers related to COVID-19, C-reactive protein (CRP), an acute inflammatory protein that increases up to 1,000-fold at sites of infection or inflammation.
With ArtemiC, the companies expect to minimize the severity of symptoms of COVID-19, which still affects more than 15 million people in India.
The commercialization of the orally inhaled drug ArtemiC will further build on an ongoing partnership between HempStreet and MGC Pharma, a European pharmaceutical company working on polyherbal formulations based on cannabis and other phytopharmaceuticals.
The partnership marks MGC Pharma’s entry into the Indian market in line with its paramount strategy of advancing phytomedicine adoption globally.
In a press release, India’s first research to retail venture in the ayurvedic cannabis sector stated: “HempStreet, through its collaboration with MGC Pharma, aims to create and bring to market phytopharma products to tackle mass ailments.”
HempStreet confirmed that ArtemiC is made up of four natural-based ingredients consisting of Curcumin, Boswellia serrata, Artemisinin, and Vitamin C.
“ArtemiC Rescue and ArtemiC Support are the two variations of the new drug product that will be available via medical practitioners and leading pharmacies,” the Indian retailer announced.
HempStreet explained that the ArtemiC Rescue is an adjunctive treatment for the symptoms of COVID-19 while ArtemiC Support is a daily supplement that does not contain artemisinin.
“HempStreet and MGC Pharma are committed to bringing thoroughly studied, incredibly effective, and ethically dispensed phytomedicines to treat widespread illnesses that affect people worldwide,” Abhishek Mohan, Founder & Chief Executive Officer (CEO) of HempStreet, reaffirmed consumers.
He argued that an estimated 15 million people in India are said to be suffering from “long covid” symptoms, making it a hidden mass ailment on its own as he expressed his readiness to partner with MGC Pharma to help patients nationwide with its products.
Furthermore, HempStreet has expanded its product portfolio with the launch of Sarpagandha Vati, a tablet that helps treat Hypertension and Insomnia due to its calmative properties.
The company informed that its Ayurvedic medicine calms the nervous system, aids in the maintenance of normal blood pressure, and maintains oxygen balance that helps regulate blood pressure in hypertensive patients.
“Sarpagandha Vati’s diuretic and detoxifying properties benefit people with various health and lifestyle issues including management of epilepsy and delirium, to combat anxiety disorder, as well as inducing natural sleep to defy Insomnia,” HempStreet added.